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Abstract:
The primary focus of the paper is to assess whether the US, which spends
significantly more than any other country in health care, has better health outcomes. It has
long been clear that mortality as a whole is not better in the US than in other countries. We
focus our analysis on the US performance for the treatment of non-fatal health outcomes and
we compare the health of the United States to that of Canada, the United Kingdom and Spain.
Our results indicate a discrepancy between high quality of life for some outcomes and low
quality of life for others. Such discrepancy is not attributable to measurement issues in
determining a person’s quality of life, nor is it attributable to differing performance by
income. Our results suggest that the discrepancy is due to the fact that the US does better for
the treatment of conditions where high-tech medicine is a key to better health and worse in
conditions requiring substantial chronic disease management.
Keywords: international comparison, healthcare systems, chronic diseases, technology,
health.COMPARING NON-FATAL HEALTH ACROSS COUNTRIES: IS THE US
MEDICAL SYSTEM BETTER?
Comparing medical care systems across countries has become a preoccupation of
policymakers.  It is commonly asserted in the United States, for example, that the Canadian
health care system is better than the US one since its per capita spending in US dollars PPP is
lower, by about 45 percent, but longevity is just as high.  The UK asserts its superiority over
France for the same reason.
Implicit in such comparisons is the idea that mortality is a good summary for the
output of the medical care system.  But this is not necessarily the case.  Many medical services
are designed not to extend life but to improve the quality of it.  Indeed, entire fields of medicine
–care for mental illness, ophthalmology services, physical therapy, gastroenterology, to name a
few– are devoted not to extending life but to increasing its quality. And even services that were
developed to extend life, such as coronary bypass surgery, are often applied in situations where
quality of life more than length of life is the goal.  
Specialists in the field, of course, recognize the limitations of mortality for
comparing health across countries. But traditionally there have been few good ways to
compare morbidity across countries.1 In this paper, we propose a methodology to compare
non-fatal health outcomes across countries and present a preliminary comparison of health
differences in the United States, Canada, the United Kingdom, and Spain.
To understand our methodology, suppose there were just one disease, say kidney
failure.  Imagine that we surveyed the population in each country, including people with and
without kidney failure, asking people “How would you rate your health: excellent, very
good, good, fair or poor?”  People with kidney failure will generally report their health as
worse than people without kidney failure (holding constant demographic and other factors),
reflecting their true lower health state.  The degree to which people with kidney failure
report themselves in worse health in different countries is a measure of how well the
medical care system –and society more generally– treats kidney failure. If the US has a
better medical care system than other countries, people with kidney failure in this US should
report themselves in relatively better health compared to people without kidney failure than
people with kidney disease do in other countries.
1 Measuring disability adjusted life years is one approach that has been taken in the literature, but this is very
controversial.  See Murray and Lopez (1996).
Note: We are grateful to the National Institutes on Aging for research support.Note that our methodology does not make a comparison of absolute levels of self-
reported health for people with kidney disease in different countries.  Rather, it compares the
relative health of those with and without kidney failure. In this respect, it follows the
approach of Cutler and Richardson (1997, 1998, 1999), who propose to measure quality of
life disutility for different conditions by how people with and without those conditions self-
report their health.  Our analysis applies this logic to an international setting.
We  implement this methodology in four countries: the United States, Canada, the
United Kingdom, and Spain.  We chose these countries because they have very different
medical care systems, and because they have readily available data on medical conditions and
self-reported health.  But even for four countries, the data are somewhat limited. We feel
comfortable making only eleven disease comparisons (and fewer than that in some cases):
heart disease, strokes, asthma or bronchitis, diabetes, arthritis, hypertension, migraine, back
problems, hearing impairments, cataracts and glaucoma. 
Our primary focus is whether the United States, which spends significantly more
than any of these other countries do on medical care, has better health outcomes.  Somewhat
to our surprise, this is not uniformly the case.  The US does clearly better on some conditions.
People suffering from heart problems, stroke or arthritis are found to be in better health in the
US than people with these conditions in the other three countries. But the US does much
worse on other conditions.  The most important of these is diabetes, where US citizens report
themselves in substantially worse health than citizens in any of the other three countries.
We  consider a number of explanations for why this may be the case.  The first
explanation is that it may reflect a problem with our self-report variable; people in some
countries may be less likely to report themselves in poor or excellent health than people in
other countries even with the same ‘true’ quality of life.  To some extent, we control for this
by comparing health for people with and without particular conditions.  As a further test, we
repeat our analysis using a more objective measure of health: the number of impairments in
basic Activities of Daily Living (ADLs) that the person has.  Our results are virtually
identical in considering ADL impairments as in looking at self-reported health, however, so
we reject this explanation.
The second hypothesis we consider is that the US does better for richer, well insured
people than for poorer, uninsured people, and these differences are reflected in the prevalence
of particular conditions.  However, we show that our results are the same when we divide
each country into rich and poor, as when we consider them together.  Thus, this explanation is
not supported.
We finally propose, and provide limited evidence for, an alternative explanation: the
US does much better in conditions where high-tech medicine is the key to better health, and
worse in conditions where low-tech management of chronic disease is more important.  This
hypothesis matches the ranking of the diseases. Heart disease and strokes are the two conditions
where high-tech medicine is most valuable, and they are the two where the US does best.
Diabetes is a condition where chronic disease management is vital, and the US does worst. With
the data at hand, we are unable to prove whether high-tech care and poor chronic disease
management are the source of the differing results, but we suggest empirical tests that could be
helpful.
The rest of the paper is organized as follows. Section 1 describes the methodology.
Section 2 describes the data and the institutional environment of the four countries we
consider. Section 3 presents our main results, and section 4 discusses possible interpretations.
The last section concludes.  
2I. Methods
When comparing the effect of medical care on non-fatal health across countries, we
have several options. One option is to look at the prevalence of particular diseases across
countries. This is an important outcome, but it suffers from two problems. First, and most
importantly, prevalence of disease will be influenced by many factors in addition to medical
care.  Thus, one would need to be cautious about such an interpretation.  Second, prevalence
alone does not account for the severity of the impairment – how much does the health system
alleviate the adverse impact of diseases.
To focus particularly on what medical care can do to influence health, we consider
the health of people who have particular conditions, ignoring the possible role of medical
care in disease prevention. Even here, there are methodological choices about how to
compare health.  One strategy is to undertake physical observations of people with different
diseases and have experts (or non-experts) rate those observations. This is a good strategy,
and we pursue it to some extent below. But physical assessment of life with diseases is
limited, and omits the enormous contribution that mental and other non-physical attributes
(such as pain) play in health.  Further, even experts in the field may not know what it is like
to live with particular diseases.  
We thus take an alternate approach to measuring the impact of the medical system.
Following Cutler and Richardson (1997, 1998, and 1999), we compare the self-reported
health of people who have a condition to the self-reported health of people who do not have
that condition. These self-reports are the individuals’ own assessment of their current health
state. Self-assessed health of people with a condition is on average below that of people
without the condition (as one would expect).  The degree to which self-reports of those with a
given condition fall below those without that condition is an indicator of the quality of life for
people with the condition. We can compare these quality of-life differentials across
countries.2
We formalize this idea with a little notation.  We assume that people have a latent
measure of health h*, which depends on the diseases they have D, demographic
characteristics  X such as sex, income or education, and the country C. Countries treat
diseases differently, and hence each disease may affect the health outcomes of people who
live there differently.  We express health of people i in country j as:
(1)
where  β, and λ are vectors of parameters to be estimated. The interaction of disease
indicators with country dummies allows for the differential effect of having each condition in
each country. We interact demographic variables with country dummies to allow for variation
along this dimension as well.  
In practice, we do not observe h*, the underlying health measure. We do observe
discrete approximations to it, denoted h. In our primary specification, the questions that we
consider are about self-reported overall health status (SRHS), generally framed as: “How
3
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2 There is another way to explain the comparison that may be helpful.  We are implicitly comparing the health
of people with each disease across countries, but scaling that by the health of people without that disease.
The scaling accounts for country-specific reporting factors that would otherwise influence the results.would you rate your health: excellent, very good, good, fair or poor?” Previous research
shows that SRHS is a good predictor of mortality as well as of other health outcomes, with
people who rate their health as poor being more likely to die or to have a bad health outcome
(Long and Marshall, 1999; Mossey and Shapiro, 1982; Kaplan et al., 1988; Idler et al., 1990).
With a distributional assumption on ε, we can relate the underlying variable to its
discrete approximation. In particular, if we assume that ε is normally distributed, we can
estimate equation 1 using an ordered probit model. This model, in addition to the coefficients
of the previous specification, will also give us estimates of c1, c2 and c3, the break points
between the four different health states (the four states are defined below).3
The  β and  γ coefficients in our model range from +∞ to -∞. To normalize the
results, we divide our coefficients by the difference between the cut points of very
good/excellent health and poor/very poor health, e.g.,                        .  If we interpret the
difference between c1 and c3 as the difference between perfect health and death, this would
correspond to the quality-adjusted life expectancy associated with each health state.  We thus
term these QALY measures.  Even if one is not willing to make this assumption, however,
the scaling provides a useful benchmark.
Self-reported health status is not necessarily a perfect measure of health. The very
nature of the self-report raises some questions. For instance, it could be the case that  diseases
have the same effect on the health of the population in different countries, but that people
perceive the impacts differently for cultural reasons.  As noted above, we believe our within-
country comparison controls for this.  We can test this further, however, using physical
measures of impairment in addition to self-reported. We thus estimate models using
impairments in activities of daily living (ADLs, including the ability to perform certain daily
habits such as bathing, dressing, walking or eating) as the dependent variable.  As we show
below, the results are similar with the two measures.
II. Selection of Countries and Data
We  focus our analysis on the health of the elderly.  In developed countries, the
elderly are virtually the only group with significant health impairments, so it makes sense to
focus on that group. We analyze the health of the elderly in four countries: the US, Canada,
the UK, and Spain. The countries were chosen partly because they have available data, and
partly because their health systems are so different. The main characteristics of the four
systems are summarized below and spending trends are shown in Figure 1.4
The United States
The United States spends the most on medical care of the four countries in our
sample – indeed, the most of any country.  Spending was $3538 per person (PPP applied), or
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3 In our basic model, we assume these cut points are the same across countries. We also have run the model
allowing the cut points to differ across countries.  The results are robust to this change.
4 A comparison of the problems faced by medical care systems internationally is in Cutler (2002).
5 All spending data are from the OECD Health Data (2002).mix of public and private insurance. There is near universal coverage for the elderly under
Medicare, but some health impairments of the elderly will have resulted from conditions
occurring earlier in life, when private insurance is more common. The receipt and quality of
private insurance is related to income. About 15 percent of the US population is without
health insurance, most predominantly the near poor population. 
Figure 1. Health Expenditure as % of GDP 
Source: OECD Health Data, 2002.
Health insurance in the United States is frequently quite generous on the demand-
side.  Patients pay relatively little for using care, and traditionally faced few restrictions on
which providers they can access. This is still true among the elderly, although there is a major
exception: Medicare does not cover costs of outpatient prescription medications. In the non-
elderly population, cost sharing is also low; most people with insurance can access medical
care without a major financial barrier.  
On the supply-side, the system is mixed. Much of private health insurance is
‘managed’, with explicit utilization restrictions placed on providers and financial incentives
inducing them to use less care. But there are no overall constraints on technological
availability, the way there are in other countries.
The National Health Interview Survey (NHIS) is the most common source of
information on disease prevalence and health status for the US, and it has been conducted
annually since 1957. Each year it includes a core set of questions on health-related variables,
with periodic supplements that include more detailed information for certain populations or
diseases. In 1994, the NHIS conducted the Second Supplement on Aging (the first was in
1984), containing detailed information about health conditions and physical functioning. We















Canada is the second most expensive system among our four countries, spending
over 9 percent of GDP on medical care in the mid-1990s. Canada has a national insurance
system (Medicare), which covers people from cradle to grave.6 The Canadian system is
administered separately in the provinces and territories, but for our purposes the similarities
are more important than the differences.
Coverage in Canada is relatively complete; there are few restrictions on the
providers that people can see. As in the US, however, pharmaceutical coverage is spotty.
Some provinces cover prescription medications for particular groups such as the elderly, and
others do not.  
For services that are covered, cost sharing in Canada is very low; patients pay very
little for the care that they receive. Access to care is rationed on the supply-side, however,
particularly for high-tech services. Governments in Canada set limits on the availability of
sophisticated services and put overall caps on hospital spending, which in turn limits how
much technology can be used. Decisions on the availability of high-tech care are made at
least in part on the basis of cost-effectiveness criteria. The Canadian Coordinating Office for
Health Technology undertakes a technology assessment, and many provinces have their own
technology assessment services. The same is true for the UK (the relevant body is the
National Institute for Clinical Excellence) and Spain (The National Office of Technology
Assessment). Use of high-tech care in Canada is far below similar use in the US (Kessler and
McClellan, 1999), as we document below.
Data on health in Canada are available in the Canadian National Population Health
Survey (NPHS).  The first cycle of data collection was in 1994, and continued surveys have
been conducted every second year thereafter. Our study includes data for 1994. The target
population of the NPHS includes residents in all provinces, with the exclusion of people
living on Indian Reserves. The sample is about 19,000 people. In each household, basic
information is collected for all its members and one person, aged 12 or older, is randomly
selected for a more in-depth interview.  
The United Kingdom
The United Kingdom is a negative outlier in almost all medical spending
comparisons. Spending on medical care is only about 7 percent of GDP.  Given the fact that
spending as a share of GDP typically rises with income, and that the UK is relatively wealthy,
this makes spending particularly low.  
The National Health Service (NHS) in the UK dates from 1948. All legal residents
are eligible for health care coverage. In addition to the public coverage, people are allowed to
purchase supplemental private insurance, or to pay physicians privately for services.  About
10.5 percent of the UK population had private insurance in 19957.  
6
6 Some of the current elderly were alive before Medicare was implemented, but they were very young, and
their late life health is unlikely to reflect this to any great extent.
7 Source: Laing and Buisson (1997).Accessing health care in the UK generally costs a patient very little.  Most health
care is free of charge at the point of use, although there is some cost sharing for some
services, including pharmaceuticals. This cost sharing is waived for the elderly (and
children). As with Canada, spending in the UK is limited on the supply-side. The government
restricts funding for hospitals and monitors technology acquisition.   Both of these steps limit
the availability of high-tech resources. 
Service efficiency has been a chronic problem in the UK. The perception of the UK
system is one of long lines and non-monetary restrictions on service use. Patients must have a
referral from a general practitioner to access specialist care. Urgent cases may be seen soon,
but non-urgent cases can have a substantial delay. To address these issues, the government in
1990 attempted to create an ‘internal market’ in medical services, where patients can choose
their primary care ‘fundholder’, and primary care providers can shop among hospitals for the
best care. The internal market was partially successful in improving the efficiency of
the system (Propper and Soderlund, 1998), but not wholly.8
Our data for the UK are from the British Household Panel Survey (BHPS). The
BHPS is not designed as a health survey, although it includes substantial information about
health status.  Questions are asked about the prevalence of certain health conditions as well as
the ADLs for the elderly. The BHPS interviews more than 5,000 households (about 10,000
individuals) per year.  Longitudinal information is collected in successive waves. The survey
also includes information regarding household organization, labor market, income, housing
and socio-economic values. We use data from 1995.  
Spain
Spain spends about 7 percent of GDP on medical care, roughly the same percentage
as the UK. The Spanish health system has changed enormously in the last 25 years since the
re-establishment of democracy and the enactment of the new Constitution in 1978. Prior to
1978, Spain had a centralized, means-tested social security system, with only 20 percent of
its population covered by public insurance in 1942 and 45 percent covered in 19609. The
Basic Social Security Act in 1967 led to an increase in public health insurance coverage to 81
percent of the population.
The 1978 Constitution established the universal right to health care and set out a
new regionally based health care system where the 17 Spanish Autonomous Communities
were responsible for the provision of health care in their territories. The process of devolution
of health care competences to the regional governments started in 198110.  Each autonomous
community is organized in health areas and basic health zones that are responsible for the
management of the health facilities and services in their geographical area. Ninety-five
percent of the Spanish population is covered by the Social Security system, with nearly all of
the remainder (civil servants) covered through a special mutual fund system. 
7
8 The Blair government has backed away from this reform somewhat, and in exchange proposes to spend
much more on medical care.
9 Data: European Observatory of Health Care Systems.
10 Through 1994, authority had been transferred to 7 of the 17 Autonomous Communities, covering 62 percent
of the Spanish population (Catalonia, Basque Country, Valencia, Galicia, Navarra, Canary Islands). Health
care in the remaining 10 is still under the control of the central state’s administration and is managed by
INSALUD (National Institute of Health). However, the devolution process back to these 10 communities
has been reactivated since 2001.The Spanish medical system covers primary health care, specialized care (inpatient and
outpatient), and pharmaceuticals. Primary and specialty care is free of charge, although there is a
40 percent copayment for pharmaceuticals, but this is waived for the elderly and those with
permanent disabilities. Among common medical care items, only dental care is not covered.
Patients have free choice of their physician11. Two forms of organization of primary
care coexist: the traditional form of organization that consisted in sole-practitioners working
part time and paid on a capitated basis and the new model, where primary care physicians are
part of a team of general practitioners working full time on a salaried basis and a small
capitation fee. Now most physicians in Spain are salaried employees of the government.  The
same is true for hospitals and ambulatory clinics. In the Spanish health system, specialists
from general hospitals rotate to cover for outpatient ambulatory services.
As with Canada and the UK, Spain also uses supply-side restrictions to control
spending, although there are some differences across autonomous communities. Most
communities use an annual budget for hospital payments but a few (i.e. Catalonia) use a
mixed funding system where the annual budget is combined with a DRG (Diagnostic Related
Group) system.
On many measures, the Spanish medical care system works very well. Accessibility is
among the highest in Europe, with 92 percent of the patients having to wait one day or less for
a consultation with a GP (Ortún and López-Casasnovas, 1999). Moreover, despite the fact that
GPs serve as gatekeepers, patients do not need a referral to see some specialists. All health care
areas have at least one main hospital and they are organized in such a way that nearly everyone
lives within an hour of a general hospital.  Because of the centralized nature of provision, Spain
can make large-scale changes in medical care quickly. As we discuss below, Spain has
emphasized strongly some measures of preventive care, such as treatment of diabetes.
To measure health in Spain, we use data from the Encuesta Nacional de Salud de
España (ENSE). The ENSE collects information about health status as well as access to care,
visits to specialists, and pharmaceutical consumption. The survey contains extra information
for the elderly (ADLs) and for children 16 or younger (diet, vaccination, breast-feeding).
The survey includes about 9,000 people and it started in 1993, continuing every two years
thereafter. In our study we include data for 1993, 1995 and 1997.
Questions about Self-Reported Health
All four surveys ask about self-reported health, with relatively similar questions.12
However, the possible responses vary slightly by countries.  In the US and Canada, there are
five responses: “poor”, “fair”, “good”, “very good” and “excellent”. In the UK and Spain, the
five responses are slightly different: “very poor”, “poor”, “fair”, “good” and “very good”.
Our within-country differencing methodology should adjust for these differences in possible
responses, but it is important to understand what effect such a wording choice can have. 
8
11 However, if patients want to choose a physician that is in another health care area, first the GP has to accept
the patient in her list.
12 For instance, the US NHIS asks “would you say that your health in general is excellent, very good, good, fair
or poor?”. The Canadian National Population Health Survey asks: “in general, how would you describe your
health: excellent; very good; good; fair; poor”. The British Household Panel Survey asks “please think back
over the last 12 months about how your health has been. Compared to people of your own age, would you say
that your health has on the whole been: excellent, good, fair, poor, very poor?”. The Spanish ENSE asks “in
the last 12 months, would you say that your health has been very good, good, fair, bad, or very bad?”To examine this, we take advantage of the fact that the US added the “very good”
choice in 1981. Prior to that year, there were only four possible responses.  Table 1 presents
the percentage of US population that reported each of the answers in 1980 and in 1982-83.
The differences in the set of people reporting fair or poor health, and good or better health,
between the two sets of answers are not statistically significant.  In light of this, we redefine
SRHS in all countries into four categories that are comparable across all four countries: poor
or very poor; fair, good, and very good or excellent.  We order the responses from 1 to four in
that order.  
Table 1.  Self.Reported Health Status in 1980 versus 1982-1983
Selection of Conditions
The NHIS in the US contains information on a vast array of chronic conditions, as
well as other measures of health such as ADL impairments. Unfortunately, this is not the case
for all countries, where the prevalence questions are much more limited. This is particularly
true in the UK, where the survey is not a dedicated health questionnaire. In light of this, and
in order to be able to compare the US with as many countries as possible, we use several sets
of comparison questions.  In the first set of results, we compare only the US and Canada,
since these are the countries for which the most conditions in common are asked about (14
total). The second set of results extends the analysis to include Spain, with fewer health
conditions in common (9 conditions). The last set of results is for all four countries. These
results have the least common conditions (8 conditions).  
Table 2 shows conditions that are available in each country.  The large set of 14
conditions includes: stroke, asthma or bronchitis, skin or allergy problems, arthritis, diabetes,
hypertension, stomach problems (ulcer and other digestive conditions), migraine, back
problems, cataracts and glaucoma, sight impairment, and hearing impairment.  
In addition to choosing comparable conditions, we need to account for the fact that
different countries might have different awareness of certain diseases, with some countries
diagnosing certain conditions more frequently. If this is the case, we might find that a country
does very well in the treatment of a certain disease simply because there is more awareness
and more mild cases are being diagnosed. 
To examine this, Table 2 presents the prevalence of these health conditions in the
four countries. We present prevalence estimates for the overall population and for the elderly.
In most of the cases there are no major differences in prevalence across countries. The
exceptions to this are skin or allergy conditions and visual impairments. The US has almost
double the share of people suffering from skin or allergy conditions, while it has a much
9
                   Summary Measures       Tabulation Measures
Excellent Very Good Good Fair Poor Excellent-Good Fair-Poor
Age 18+
.  1980 49% … 38% 9% 3% 88% 12%
   1982-83 40% 25% 24% 8% 3% 89% 11%
Age 65+
.  1980 29% … 41% 22% 9% 69% 31%
   1982-83 16% 19% 31% 22% 12% 66% 34%
Source: Authors' Calculations based on the National Health Interview Surveylower percentage of its population suffering from visual impairments.13 Given this, when
analyzing our results we downweight the results for these two conditions, and focus instead
on the others.  
Table 2. Chronic Condition Prevalence Rate per 1000 People
III. Main Results
We present our main results in three tables.  Table 3 compares the US and Canada, the
countries with the most data.  Table 4 adds Spain to the comparison, and Table 5 adds the UK.
Tables 4 and 5 have fewer conditions than Table 3, reflecting the smaller number of comparable
conditions asked about in different countries. In each case, the dependent variable is the
person’s self-reported health status, reported on a 1 to 4 scale as previously defined, where a
higher number is better health.  Thus, a negative coefficient indicates that a particular condition
adversely affects health. The first column of each table reports results for the entire elderly
sample, and the second column normalizes the coefficients dividing them by the cut points 1
and 3. We term this the QALY estimate, although that particular interpretation is not central to
our results. The third to sixth columns are discussed in the next section.  
Consider first table Table 3.  As expected, the diseases all have a negative impact on
self-reported health. The ones with the largest impact are asthma or bronchitis, heart
problems and strokes.  The normalized coefficients in the second column imply that asthma
or bronchitis would have a QALY weight for the US of 0.800 (1-0.200). The QALY weight
for the US for heart disease is 0.841 and for stroke 0.710. The relative QALY rankings are
consistent with our expectations.
10
                US          CANADA            SPAIN             UK
All 65+ All 65+ All 65+ All 65+
Endocrine
  Diabetes 35.8 147.20 30.20 111.90 36.00 138.80 24.20 124.10
Circulatory
   Hypertension 125.10 339.20 106.90 286.50 119.10 303.60 … …
   Stroke 14.10 47.70 8.60 39.60 …………
   Heart Problems 60.80 257.20 38.00 175.10 48.10 238.30 … …
   Circulatory Probl. 138.80 409.80 110.00 380.80 109.00 387.30 123.30 388.60
Musculoskeletal
   Arthritis 134.77 581.95 126.90 504.40 81.90 533.50 147.50 535.80
   Back Probl. 70.10 122.70 81.20 124.50 …………
Respiratory
   Asthma/Bronchitis 116.34 106.80 85.30 97.50 119.10 107.60 113.50 188.20
Digestive
   Stomach/Ulcer Probl. 28.30 48.30 33.00 49.70 38.80 61.70 35.20 60.70
Impairments
   Cataracts 25.70 102.20 23.90 139.30 …………
   Glaucoma 10.80 35.30 9.90 46.30 …………
   Sight Probl. 50.10 86.35 79.80 126.70 88.50 123.10 … 128.50
   Hearing Probl. 93.10 322.10 58.10 214.90 82.60 263.10 … …
Other
   Skin/Allergy 152.30 194.70 125.20 114.20 80.00 72.20 115.20 87.40
SOURCES: US (National Health Interview Survey); Canada (National Population Health Survey); UK (British Household Panel Survey); Spain (Encuesta Nacional de Salud)
13 In the case of visual impairment, there is an issue about how people respond if they use glasses or contact
lenses and that corrects the problem.Table 3. US and Canada
Dependent variable: Self-reported health
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DEPENDENT VARIABLE: SELF-REPORTED HEALTH
    ALL               POOR            NON-POOR
Coefficients DQALY Coefficients DQALY Coefficients DQALY
Asthma or Bronchitis  -0.359**  -0.200  -0.310** -0,175  -0.523** -0,276
[0.087] [0.107] [0.140]
Asthma/Bronch*Canada  -0.317*  -0.177 -0,251 -0,142  -0.555** -0,294
[0.171] [0.205] [0.273]
Skin/Allergy -0,0004  0.000 -0,033 -0,019 0,084 0,044
[0.058] [0.068] [0.116]
Skin/Allergy*Canada -0,092  -0.051 -0,038 -0,021 -0,219 -0,116
[0.082] [0.099] [0.155]
Arthritis  -0.039**  -0.022  -0.052** -0,029 0,029 0,015
[0.014] [0.025] [0.090]
Arthritis*Canada  -0.288**  -0.161  -0.309** -0,175  -0.291** -0,154
[0.060] [0.071] [0.115]
Diabetes  -0.476** -0,266  -0.636** -0,360  -0.468** -0,247
[0.081] [0.094] [0.109]
Diabetes*Canada  0.348** 0,194   0.369** 0,209 0.338* 0,178
[0.103] [0.121] [0.200]
Hypertension  -0.222** -0,124  -0.221** -0,125  -0.204** -0,108
[0.033] [0.038] [0.070]
Hypertension*Canada -0,020 -0,011 -0,019 -0,011 -0,123 -0,065
[0.054] [0.064] [0.100]
Heart  -0.284** -0,159  -0.218** -0,123  -0.477** -0,252
[0.056] [0.065] [0.104]
Heart *Canada  -0.241** -0,135  -0.241** -0,136  -0.238* -0,126
[0.073] [0.087] [0.134]
Stroke  -0.527** -0,294  -0.488** -0,276  -0.735** -0,388
[0.120] [0.134] [0.269]
Stroke *Canada  -0.182** -0,102  -0.228* -0,129 -0,122 -0,064
[0.052] [0.130] [0.315]
Migraine  -0.557** -0,311  -0.586** -0,331  -0.420* -0,222
[0.110] [0.126] [0.232]
Migraine *Canada 0,181 0,101 0,213 0,120 0,064 0,034
[0.141] [0.168] [0.279]
Back  -0.207** -0,116  -0.218** -0,123 -0,116 -0,061
[0.090] [0.105] [0.174]
Back *Canada -0,058 -0,032 -0,054 -0,031 -0,146 -0,077
[0.102] [0.0121] [0.195]
Stomach  -0.282* -0,157  -0.259** -0,146  -0.611** -0,323
[0.168] [0.132] [0.303]
Stomach *Canada 0,163 0,091   0.286* 0,162 0,438 0,231
[0.189] [0.168] [0.353]
Cataracts -0,029 -0,016 -0,062 -0,035 0,087 0,046
[0.069] [0.080] [0.143]
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    ALL               POOR            NON-POOR
Coefficients D QALY Coefficients D QALY Coefficients D QALY
Glaucoma -0,023 -0,013 -0,046 -0,026 0,004 0,002
[0.118] [0.139] [0.229]
Glaucoma*Canada 0,096 0,054 0,171 0,097 -0,023 -0,012
[0.147] [0.176] [0.272]
Sight  -0.263** -0,147  -0.229** -0,129  -0.347** -0,183
[0.067] [0.077] [0.137]
Sight*Canada  0.238** 0,133  0.235** 0,133 0,279 0,147
[0.088] [0.102] [0.179]
Hearing 0,040 0,022 0,029 0,016 0,081 0,043
[0.048] [0.056] [0.096]
Hearing*Canada  -0.230** -0,128 -0,175 -0,099  -0.399** -0,211
[0.090] [0.109] [0.151]
Canada   0.573** 0,320  0.755** 0,427 0,344 0,182
[0.200] [0.256] [0.357]
Age  -0.125* …. -0,103 …. -0,137 ….
[0.069] [0.080] [0.139]
Age Square 0,021 …. 0,022 …. 0,009 ….
[0.014] [0.016] [0.029]
Male -0,130 …. -0,074 …. -0,282 ….
[0.116] [0.144] [0.206]
Age* Male 0,021 …. -0,079 …. 0,219 ….
[0.109] [0.132] [0.205]
Age Square*Male -0,004 …. 0,013 …. -0,028 ….
[0.022] [0.026] [0.043]
Income 1.1E-5** …. 2.0E-5** …. 1,90E-06 ….
[9.4E-7] [2.2E-6] [2.7E-6]
Income*Canada  -3.8E-6** ….  -2.1E-5** …. 4,30E-06 ….
[1.5E-6] [4.6E-6] [3.3E-6]
High School+ 0.384** …. 0.347** …. 0.415** ….
[0.032] [0.041] [0.052]
HighSchool+ *Canada  -0.105** …..  -0.153** …. -0,121 ….
[0.054] [0.076] [0.086]
Cutting Points
_Cut 1 -1,192 -1,028 -1,648
_Cut2 -0,324 -0,161 -0,750
_Cut3 0,599 0,741 0,246
Robust standard errors are reported in parentheses
** Significant at 5 percent
*Significant at 10 percent
All Poor Non-Poor
Coefficients ∆ ∆Qaly Coefficients ∆ ∆Qaly Coefficients ∆ ∆QalyTable 4. US, Canada and Spain
Dependent variable: Self-reported health
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    ALL               POOR            NON-POOR
Coefficients D QALY Coefficients D QALY Coefficients D QALY
Hypertension  -0.233** -0,126  -0.231** -0,127  -0.218** -0,112
[0.034] [0.038] [0.071]
Hypertension*Spain   0.050* 0,027 0,062 0,034 -0,010 -0,005
[0.027] [0.081] [0.138]
Hypertension*Canada -0,050 -0,027 -0,014 -0,008 -0,144 -0,074
[0.054] [0.065] [0.102]
Asthma/ Bronchitis  -0.348** -0,189  -0.295** -0,162  -0.524** -0,268
[0.088] [0.109] [0.143]
Asthma/Bronch*Spain  -0.238* -0,129  -0.291* -0,160 -0,121 -0,062
[0.135] [0.167] [0.236]
Asthma/Bronch*Canada  -0.332* -0,180 -0,256 -0,141  -0.608** -0,031
[0.173] [0.205] [0.291]
Skin/Allergy -0,009 -0,005 -0,038 -0,021 0,073 0,037
[0.059] [0.069] [0.116]
Skin/Allergy*Spain  -0.244** -0,132  -0.253* -0,139 -0,198 -0,101
[0.112] [0.138] [0.218]
Skin/Allergy*Canada -0,124 -0,067 -0,063 -0,035  -0.270* -0,138
[0.083] [0.100] [0.156]
Diabetes  -0.492** -0,267  -0.556** -0,305  -0.271* -0,139
[0.083] [0.095] [0.151]
Diabetes*Spain  0.405** 0,219  0.386** 0,212  0.371** 0,190
[0.116] [0.138] [124]
Diabetes*Canada 0,126 0,068 0.247** 0,136 0,246 0,126
[0.105] [0.123] [0.204]
Arthritis -0,043 -0,023 -0,056 -0,031 0,029 0,015
[0.043] [0.049] [0.090]
Arthritis*Spain  -0.488** -0,210  -0.540** -0,297  -0.513** -0,263
[0.086] [0.099] [0.178]
Arthritis*Canada  -0.352** -0,191  -0.372** -0,204  -0.362** -0,185
[0.059] [0.070] [0.114]
Heart Problems  -0.334** -0,181  -0.264** -0,145  -0.547** -0,280
[0.055] [0.064] [0.104]
Heart *Spain  -0.086** -0,047 -0,160 -0,088  -0.239** -0,122
[0.037] [0.122] [0.098]
Heart*Canada  -0.240** -0,130  -0.241** -0,132  -0.214* -0,110
[0.074] [0.088] [0.118]
Stomach Conditions  -0.267* -0,145  -0.241* -0,132  -0.616** -0,315
[0.157] [0.127] [0.306]
Stomach*Spain 0,382 0,207 0,352 0,193 0,467 0,239
[0.202] [0.233] [0.359]
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    ALL               POOR            NON-POOR
Coefficients D QALY Coefficients D QALY Coefficients D QALY
Sight  -0.283** -0,153  -0.246** -0,135  -0.381** -0,195
[0.068] [0.076] [0.139]
Sight*Spain  0.190* 0,103 0,123 0,068 0,352 0,180
[0.108] [0.125] [0.221]
Sight*Canada 0.262** 0,142 0.257** 0,141 0.299* 0,153
[0.090] [0.104] [0.181]
Hearing 0,043 0,023 0,025 0,014 0,099 0,051
[0.048] [0.055] [0.099]
Hearing*Spain  -0.139* -0,075 -0,152 -0,084 -0,069 -0,035
[0.085] [0.099] [0.171]
Hearing*Canada  -0.290** -0,157  -0.240** -0,132  -0.452** -0,231
[0.090] [0.109] [0.153]
Spain  -0.108* -0,059 -0,109 -0,060  -0.583** -0,298
[0.065] [0.138] [0.182]
Canada 0.789** 0,427 0.981** 0,539 0.606** 0,310
[0.072] [0.103] [0.194]
Age  -0.134** …. -0,108 …. -0,151 ….
[0.066] [0.077] [0.133]
Age Square 0.024* …. 0,024 …. 0,013 ….
[0.013] [0.015] [0.027]
Male -0,117 …. -0,056 …. -0,261 ….
[0.110] [0.136] [0.196]
Age* Male 0,031 …. -0,067 …. 0,205 ….
[0.104] [0.126] [0.195]
Age Square*Male -0,007 …. 0,009 …. -0,025 ….
[0.021] [0.025] [0.040]
Income 1.1E-5** …. 2.0E-5** …. 1,90E-06 ….
[9.5E-7] [2.2E-6] [2.8E-6]
Income*Spain  -1.1E-5** ….  -2.0E-5** …. -1,80E-06 ….
[9.5E-7] [2.2E-6] [2.8E-6]
Income*Canada  -3.9E-6** ….  -2.1E-5** …. 4,30E-06 ….
[1.6E-6] [4.7E-6] [3.4E-6]
High school+ 0.391** …. 0.353** …. 0.429** ….
[0.032] [0.042] [0.053]
High school+ *Spain  -0.217* …. -0,105 …..  -0.324** ….
[0.111] [0.166] [0.159]
High school+*Canada  -0.128** ….  -0.178** ….  -0.145* ….
[0.055] [0.077] [0.087]
Cutting Points
_Cut 1 -1,199 -1,022 -1,683
_Cut2 -0,299 -0,125 -0,750
_Cut3 0,647 0,798 0,271
Robust standard errors are reported in parentheses
All Poor Non-Poor
Coefficients ∆ ∆Qaly Coefficients ∆ ∆Qaly Coefficients ∆ ∆QalyThe different impact between the US and Canada is reflected in the coefficient on
the interaction between the Canada dummy variable and each disease. For example, the
positive coefficient on diabetes * Canada in the eighth row of the table indicates that people
with diabetes in Canada are relatively better off than they are in the US. The fact that the
interaction term is less than the main effect in the first row indicates that even in Canada,
people with diabetes are not in better health than people without diabetes.  
The interaction terms between the Canada dummy and the different illnesses are not
of a uniform sign. The US does statistically significantly better in the treatment of strokes,
heart problems, arthritis, asthma or bronchitis, and hearing, but it does poorly in the treatment
of diabetes.  There are no significant differences in the treatment of hypertension, migraines,
stomach problems (ulcers and other digestive problems) and back problems. For instance,
people in Canada suffering from heart problems have a QALY weight of 0.71, while those in
the US would have a QALY of 0.84.  People that have a stroke in Canada have a QALY of
0.61, while those that suffered a stroke in the US have a higher QALY of 0.71. The opposite
is the case for the treatment of diabetes, where people in Canada have a QALY weight of
0.82 while diabetics in the US have QALY weight of only 0.62.
Our regression also includes demographic and socioeconomic explanatory variables.
As expected, income and education have a positive effect on health, and age has a negative
effect, with older people being less healthy. Sex has no significant effect.  
Table 4 compares the US, Canada and Spain, considering 9 different illnesses.
Again, all the conditions have a negative impact on SHRS.  Once again, there is a mixed
result in looking at the country-specific interactions.  Compared to Canada, the US is still the
country with the best health care for heart conditions, asthma, arthritis and hearing, but it
does poorly in the treatment of diabetes. Strokes are not asked about in Spain so this
condition is not reported in the table. 
This pattern of findings is generally true in comparing the US and Spain as well.
The US does better than Spain in heart conditions, asthma, hearing conditions, and arthritis.
Spain does significantly better than US in the treatment of diabetes and hypertension.  The
relatively poor performance of the US in care for diabetics is a common theme of our
findings.
While not the immediate focus of our results, we comment on the Spain-Canada
comparisons as well.  In general, there is no clear winner between the two countries. Spanish
people suffering from diabetes are clearly better off than those from Canada, but Canadians
with arthritis are better off than Spaniards with arthritis.  Most other conditions are about the
same.
Income and education have a positive effect on health in all three countries, although
the income effect is more important for the US and Canada than for Spain, and education is
more important for the US. Again, age has a negative effect on health, although this effect
decreases as people grow older.
Finally, Table 5 includes all four countries: the US, Canada, Spain and UK.
Compared to the other countries, people in the US with heart and circulatory conditions,
arthritis and hearing conditions still report themselves to be in the best health, while people
with diabetes and stomach conditions report themselves worse off.  Once again, Spain is the
country with the best treatment for diabetes and the worst treatment for arthritis. Canadians
with hearing problems are worse off than in any other country.
15Table 5. US, Canada, Spain and UK
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DEPENDENT VARIABLE: SELF-REPORTED HEALTH
   ALL               POOR            NON-POOR
Coefficients ∆ ∆ QALY Coefficients ∆ ∆ QALY Coefficients ∆ ∆ QALY
Asthma/Bronchitis  -0.317** -0.167  -0.263** -0.142  -0.503** -0.245
[0.090] [0.111] [0.148]
Asthma/Bronch*UK  -0.345** -0.181  -0.383** -0.206  -0.208* -0.101
[0.112] [0.149] [0.115]
Asthma/Bronch*Canada  -0.409** -0.215 -0.337 -0.182  -0.641** -0.313
[0.178] [0.211] [0.306]
Asthama/Bronch*Spain  -0.310** -0.163  -0.359** -0.193 -0.183 -0.089
[0.137] [0.167] [0.241]
Skin/Allergy 0.009 0.005 -0.022 -0.012 0.096 0.047
[0.061] [0.071] [0.121]
Skin/Allergy*UK -0.143 -0.075 -0.049 -0.026  -0.279* -0.136
[0.101] [0.155] [0.158]
Skin/Allergy*Canada  -0.153* -0.080 -0.080 -0.043  -0.331** -0.161
[0.085] [0.101] [0.161]
Skin/Allergy*Spain  -0.261** -0.137  -0.276** -0.149 -0.215 -0.105
[0.113] [0.137] [0.223]
Diabetes  -0.471** -0.248  -0.532** -0.287  -0.244** -0.119
[0.085] [0.097] [0.112]
Diabetes*UK  0.173** 0.091 0.129 0.070  0.236** 0.115
[0.098] [0.183] [0.103]
Diabetes*Canada 0.176* 0.093 0.205* 0.110  0.324* 0.158
[0.093] [0.125] [0.170]
Diabetes*Spain 0.268** 0.141 0.350** 0.189 0.237 0.116
[0.116] [0.138] [0.228]
Stomach  -0.251* -0.132 -0.223 -0.120  -0.625** -0.305
[0.129] [0.193] [0.310]
Stomach*UK  0.261** 0.137 0.266 0.143 0.159 0.078
[0.138] [0.223] [0.124]
Stomach*Canada 0.152 0.080 0.214 0.115 0.340 0.166
[0.196] [0.216] [0.373]
Stomach*Spain 0.128 0.067 0.388 0.209 0.475 0.232
[0.206] [0.238] [0.358]
Heart/ Hypertension  -0.095** -0.050 -0.063 -0.034  -0.193** -0.094
[0.039] [0.045] [0.077]
Heart/Hyper*UK  -0.325** -0.171  -0.397** -0.214  -0.205** -0.100
[0.061] [0.082] [0.100]
Heart/Hypert*Canada  -0.367** -0.193  -0.350** -0.189  -0.391** -0.191
[0.057] [0.068] [0.106]
Heart/Hypert*Spain  -0.204** -0.107  -0.223** -0.120 -0.149 -0.073
[0.070] [0.082] [0.136]
Arthritis -0.012 -0.006 -0.027 -0.015 -0.066 -0.032
[0.044] [0.051] [0.093]
Arthritis*UK  -0.469** -0.247  -0.371** -0.200  -0.598** -0.292
[0.064] [0.084] [0.114]
Arthritis*Canada  -0.391** -0.206  -0.409** -0.220  -0.405** -0.198
[0.061] [0.072] [0.118]
Arthritis*Spain  -0.626** -0.329  -0.668** -0.360  -0.579** -0.282
[0.087] [0.099] [0.180]
Sight  -0.292** -0.154  -0.253** -0.136  -0.408** -0.199
[0.070] [0.080] [0.145]
Sight*UK  0.173* 0.091 0.237* 0.128 0.250 0.122
[0.099] [0.136] [0.170]
Sight*Canada 0.259** 0.136 0.259** 0.140 0.285 0.139
[0.093] [0.106] [0.187]
CONTINUE… CONTINUED....Table 5 (continued)
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   ALL               POOR            NON-POOR
Coefficients ∆ ∆ QALY Coefficients ∆ ∆ QALY Coefficients ∆ ∆ QALY
Sight*Spain 0.195* 0.103 0.117 0.063 0.386* 0.188
[0.110] [0.126] [0.227]
Hearing -0.085 -0.045 -0.065 -0.035 -0.148 -0.072
[0.069] [0.056] [0.102]
Hearing*UK  -0.170** -0.089 -0.116 -0.063  -0.261** -0.127
[0.074] [0.104] [0.126]
Hearing*Canada  -0.349** -0.183  -0.294** -0.158  -0.519** -0.253
[0.092] [0.110] [0.158]
Hearing*Spain  -0.186** -0.098  -0.198* -0.107 -0.118 -0.058
[0.087] [0.100] [0.178]
UK  0.567** 0.298 0.704** 0.379 0.285* 0.139
[0.056] [0.123] [0.152]
Canada 0.884** 0.465 1.088** 0.586 0.716** 0.349
[0.074] [0.105] [0.202]
Spain -0.035 -0.018 -0.100 -0.054  -0.544** -0.265
[0.066] [0.139] [0.189]
Age  -0.111* …. -0.103 …. -0.081 -0.040
[0.062] [0.073] [0.120]
Age Square 0.018 …. 0.022 …. -0.003 -0.001
[0.012] [0.014] [0.024]
Male -0.058 …. -0.032 …. -0.132 ….
[0.103] [0.132] [0.175]
Age* Male -0.028 …. -0.102 …. 0.066 ….
[0.098] [0.122] [0.172]
Age Square*Male 0.007 …. 0.017 …. 0.005 ….
[0.020] [0.024] [0.035]
Income 1.2E-5** …. 2.1E-5** …. 2.10E-06 ….
[9.7E-7] [2.3E-6] [2.9E-6]
income*UK  1.2E-5** …. -2.80E-05 ….  1.7E-5** ….
[4.3E-6] [3.1E-5] [5.9E-6]
Income*Canada  -4.2E-6** ….  -2.2E-5** …. 4.30E-06 ….
[1.6E-6] [4.8E-6] [4.5E-6]
Income*Spain  -1.1E-5** ….  -2.1E-5** …. -1.90E-06 ….
[9.7E-7] [2.3E-6] [2.9E-6]
High school+ 0.400** …. 0.359** …. 0.443** ….
[0.033] [0.042] [0.054]
High school+ *UK  -0.356** ….  -0.256** ….  -0.435** ….
[0.063] [0.099] [0.089]
High school+*Canada  -0.134** ….  -0.187** ….  -0.155* ….
[0.056] [0.079] [0.090]
High school+*Spain  -0.217* …. -0.089 ….  -0.338** ….
[0.114] [0.168] [0.166]
Cutting Points
_Cut 1 -1.132 -0.956 -1.619
_Cut2 -0.222 -0.050 -0.669
_Cut3 0.770 0.900 0.431
Robust standard errors are reported in parenthesis Robust standard errors are reported in parentheses.To  help with summary interpretations, Table 6 shows the relative ranking of
countries by conditions.  More *’s in any cell indicate that the country does better.  Looking
at any particular country yields a mixed result – every country does well for some conditions
and worse for others.
Table 6. Summary of Country Comparisons
Overall, these results lead us to reject the hypothesis that the US has clearly superior
outcomes compared to other developed countries. The US has better outcomes for heart
disease, asthma or bronchitis, and arthritis, and significantly worse outcomes for diabetes and
stomach problems. We cannot say that higher spending in the US buys significantly improved
health across the board.
IV. Possible Explanations
The important question raised by the previous section is how to explain the differing
results across countries.  We raise and test three explanations.
Differences Between Rich and Poor
One possible explanation for these results is that outside of the US, countries have
universal coverage systems, while that is not true in the US.  As a result, the US may have
better outcomes for the insured (since overall medical spending is the highest), but worse
outcomes for the uninsured.  In the elderly population that we analyze, of course, there is no
difference in insurance status in the US; virtually everyone over age 65 in the US is enrolled
in Medicare.  But there are differences in insurance coverage in the non-elderly population,
and these may translate into health differences during the retirement years. 
To test this hypothesis, we separate our population into two groups: poor and non-
poor, and we run the same model for the two types. Poor is not synonymous with uninsured,
18
Condition US Canada Spain UK
Asthma/Bronchitis **** * *** **
Skin/Allergy **** *** * ***
Diabetes * *** **** **
Stomach * *** ** ****
Heart/ Hypertension **** * *** **
Arthritis **** *** * **
Sight * **** *** **
Hearing **** * ** ***
Hypertension *** ** ****
Heart Problems **** ** ***
Stroke **** ***
Migraine *** ****
Back Problems **** ***
Cataracts *** ****
Glaucoma *** ****
**** corresponds to the country that does best for the treatment of this condition
*** is the second best, ** the third best and so on.
Dependent  variable: Self-reported healthbut the two are correlated.  Since we do not know about lifetime insurance coverage in the
NHIS, income while elderly is a reasonably proxy.  To classify people as “poor” we look at the
whole population 18 or older and determine the level corresponding to the lower thirty-third
percentile for that country.  Any individual that has an income below the thirty-third percentile
level is poor.  We use income data for the entire population because we want to know the level
of income for the elderly in the society as a whole, not just among the older population.
The third and fifth columns of Tables 3 to 5 present the results for poor and non-
poor individuals respectively. In general, our results are very similar for rich and poor people:
for conditions where the US does better than the other countries, both non-poor and poor do
better, and for conditions where the US does worse, both poor and non-poor do worse.  For
example, among people affected by heart disease, the QALY weight for the poor is 0.74 and
0.88 in Canada and the US, respectively. The QALY weight of the non-poor is 0.62 in
Canada and 0.76 in the US. Similarly, for those suffering from diabetes, the QALY weight of
the poor in Canada is 0.85 and the weight for the US poor is 0.64. For non-poor Canadians,
the weight is 0.92, while it is 0.75 in the US.
The third and fifth columns of Tables 4 and 5 expand the countries to include Spain
(Table 4) and the UK (Table 5).  The results are similar to the previous ones.  For conditions
where the US does better than the other countries, it does better for both poor and non-poor,
and for conditions where the US does less well than the other countries, both poor and non-
poor do less well.  We thus reject the hypothesis that the pattern of results is explicable by
differing effects by income.
Subjective Health Reporting
There are several possible limitations in using self-reported health status as a measure
of an individual’s health.  One important concern is that people in different countries may
perceive their health differently for cultural reasons.  If people in Canada are less likely to
report their health as very bad, this could influence our results. Norming by the overall
population responses controls for this to some extent, but may not do so completely.  Responses
outside the typical range of the overall population may not be well captured by this adjustment.
To test for this, we have repeated the results using a more objective health measure: the
number of ADLs that the individual has. ADLs are basic measures of functional status reflecting
the ability to live independently and without substantial assistance. Not all countries ask about
the same ADLs.  As with our earlier regressions, we look at the common ADLs for each set of
countries. The number of common conditions declines as we include more countries.  
In particular, comparing the US and Canada, we can measure consistently 6 ADLs:
preparing meals, shopping for groceries, walking, showering, doing light housework and
doing heavy housework.  When we add Spain to the sample, we drop one ADL (doing heavy
housework). There were no common questions between the UK and Canada regarding their
population’s ability to perform certain activities of daily living, but the UK, Spain, and the
US each asked about two different ADLs: difficulty in dressing, and walking.  Hence our last
analysis compares just these three countries.
There are a few, relatively minor, differences between this specification of the model
and the previous one. The first one is due to the fact that we had to use the data from the
NHIS Second Supplement on Aging for the US and hence we have a lower number of
observations.14 Also, given that our dependent variable is not qualitative, we use an OLS
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14 The supplement on aging is restricted to the population aged 65 and older.  We impose this restriction in the
other countries as well.specification instead of an ordered probit. Note in interpreting the results that a higher
number of ADL impairments is worse health; thus, a positive effect of an explanatory
variable implies that the individual is worse off.  
Tables 7 through 9 show the results for the number of ADL impairments. The results
of this analysis are very similar to those using self-reported health.  As expected, for all the
three columns, the different health conditions have a positive effect on the number of ADLs
and, hence, a negative effect on the individual’s health. Once again, the US has a positive
performance in the treatment of heart problems and a negative one for the treatment of
diabetes. This is true when we compare the US and Canada, or when we add Spain and the
UK to the samples. Our results using the number of ADLs as a measure of health thus
strongly confirm our previous findings.
Table 7. US and Canada
Dependent variable: SUM ADLs
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DEPENDENT VARIABLE: SUM ADLs
All Poor Non-Poor
Asthma or Bronchitis 0.354** 0.367** 0.280**
[0.041] [0.047] [0.079]
Asthma/Bronch*Canada 0,026 -0,003 0,064
[0.091] [0.116] [0.155]
Skin/Allergy 0,024  -0.262** 0,03
[0.070] [0.090] [0.135]
Skin/Allergy*Canada 0.277** 0.351** 0.215**
[0.104] [0.132] [0.172]
Arthritis 0.312** 0.345** 0.200**
[0.035] [0.041] [0.067]
Arthritis*Canada 0,026 -0,014 0,116
[0.058] [0.075] [0.101]
Diabetes 0.427** 0.541** 0.354**
[0.045] [0.050] [0.102]
Diabetes*Canada  -0.130**  -0.128**  -0.317**
[0.057] [0.056] [0.158]
Hypertension 0.070** 0.064* 0,055
[0.033] [0.039] [0.064]
Hypertension*Canada -0,044 -0,090 0,099
[0.059] [0.077] [0.100]
Heart 0.399** 0.305** 0.348**
[0.035] [0.040] [0.072]
Heart *Canada 0.094** 0.073* 0.078**
[0.041] [0.042] [0.033]
Stroke 1.104** 1.170** 0.603**
[0.058] [0.066] [0.122]
Stroke *Canada 0.155** 0.104* 0.490*
[0.069] [0.055] [0.287]
Migraine -0,139 -0,127 -0,328
[0.170] [0.190] [0.364]
Migraine *US 0,109 0,156 0,205
[0.208] [0.258] [0.396]
Back 0,136 0.229* 0,212
[0.100] [0.117] [0.169]
Back *Canada 0,164 0,112 0.422**
[0.119] [0.146] [0.192]
Stomach 0.449** 0.531** 0,736
[0.194] [0.212] [0.415]
Stomach *Canada -0,138 -0,192 -0,521
[0.226] [0.259] [0.448]
Cataracts -0,080  -0.125** 0,029
[0.036] [0.042] [0.072]
Cataracts *Canada 0.159** 0,117 0.239*
[0.078] [0.098] [0.137]Tabla 7 (continued)
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All Poor Non-Poor
Glaucoma 0.117** 0.145** 0,077
[0.054] [0.061] [0.116]
Glaucoma*Canada -0,040 0,106 -0,304
[0.128] [0.188] [0.171]
Sight 0.593** 0.676** 0.254**
[0.042] [0.048] [0.090]
Sight*Canada  -0.676**  -0.749**  -0.319**
[0.075] [0.098] [0.126]
Hearing 0.072** -0,048 0,139
[0.034] [0.039] [0.127]
Hearing*Canada 0.380** 0.378** 0.361**
[0.116] [0.151] [0.180]
Canada  -0.556**  -0.344**  -1.003**
[0.083] [0.167] [0.248]
Age  -0.554**  -0.685** -0,186
[0.102] [0.123] [0.192]
Age Square 0.151** 0.173** 0.088**
[0.019] [0.023] [0.037]
Male  -0.343*  -0.573** 0,230
[0.173] [0.225] [0.284]
Age* Male 0,034 0,219  -0.440*
[0.148] [0.189] [0.252]
Age Square*Male -0,024 -0,052 0,050
[0.029] [0.036] [0.050]
Income  -10.0E-6**  -1.6E-5**  -9.1E-6**
[1.2E-6] [2.8E-6] [3.4E-6]
Income*Canada  -0.002* -0,031 2,80E-02
[0.001] [0.028] [0.021]
High School+  -0.068* -0,054 -0,062
[0.040] [0.051] [0.063]
High school+ *Canada 0,073 -0,046 0,071
[0.060] [0.096] [0.089]
_constant 1,352 1.558** 1.069**
[0.133] [0.166] [0.279]
Robust standard errors are reported in parentheses
** Significant at 5 percent
*Significant at 10 percent
4 age categories are included
Sum ADL=preparing meals+shopping for groceries+doing light housework
+doing heavy housework+showering+walkingTabla 8. US, Canada and Spain
Dependent variable: SUM ADLs
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ALL POOR NON-POOR
Hypertension 0.122** 0.096** 0.173**
[0.028] [0.033] [0.055]
Hypertension*Spain -0.043 0.019 -0.163
[0.070] [0.088] [0.115]
Hypertension*Canada  -0.084* 0.029 -0.08
[0.049] 0.064] [0.081]
Asthma/ Bronchitis 0.247** 0.258** 0.185**
[0.034] [0.040] [0.066]
Asthma/Bronch*Spain -0.007 -0.047 0.089
[0.113] [0.133] [0.209]
Asthma/Bronch*Canada -0.007 -0.042 0.056
[0.076] [0.097] [0.128]
Skin/Allergy -0.215 -0.217 -0.243
[0.166] [0.177] [0.161]
Skin/Allergy*Spain 0.148 0.147 0.184
[0.136] [0.172] [0.187]
Skin/Allergy*Canada 0.254** 0.306** 0.247*
[0.087] [0.110] [0.147]
Diabetes 0.432** 0.420** 0.447**
[0.039] [0.042] [0.095]
Diabetes*Spain  -0.388**  -0.404**  -0.352**
[0.092] [0.110] [0.171]
Diabetes*Canada  -0.157* -0.023  -0.416**
[0.083] [0.109] [0.135]
Arthritis 0.176** 0.215** 0.055
[0.030] [0.035] [0.058]
Arthritis*Spain 0.373** 0.402** 0.367**
[0.102] [0.121] [0.176]
Arthritis*Canada 0.071 0.024 0.172**
[0.047] [0.060] [0.081]
Heart Problems 0.151** 0.189** 0.134**
[0.030] [0.034] [0.063]
Heart *Spain 0.096** 0.084** 0.082*
[0.044] [0.039] [0.043]
Heart*Canada 0.096* 0.08 0.129*
[0.050] [0.078] [0.071]
Stomach Conditions 0.352** 0.302 0.257**
[0.113] [0.187] [0.105]
Stomach*Spain -0.258 -0.119 -0.116
[0.219] [0.259] [0.425]





Sight 0.598** 0.630** 0.454**
[0.035] [0.039] [0.073]
Sight*Spain  -0.354**  -0.449** -0,025
[0.099] [0.113] [0.207]
Sight*Canada  -0.639**  -0.661**  -0.457**
[0.061] [0.081] [0.098]
Hearing -0,054 -0,041 -0,090
[0.038] [0.033] [0.059]
Hearing*Spain 0.275** 0,160 0.507**
[0.090] [0.103] [0.182]
Hearing*Canada 0.164** -0,013 0,216
[0.094] [0.155] [0.146]
Spain  -0.605**  -0.549**  -0.758**
[0.071] [0.145] [0.205]
Canada  -0.524**  -0.372**  -1.031**
[0.066] [0.134] [0.204]
Age  -0.502**  -0.587** -0,226
[0.078] [0.093] [0.149]
Age Square 0.137** 0.150** 0.089**
[0.015] [0.018] [0.030]
Male -0,167 -0,265 0,135
[0.129] [0.164] [0.221]
Age* Male 0,051 0,166 -0,251
[0.114] [0.142] [0.201]
Age Square*Male -0,024 -0,040 0,021
[0.022] [0.028] [0.040]
Income  -6.9E-6**  -1.6E-5**  -6.6E-6**
[1.0E-6] [2.4E-6] [2.9E-6]
Income*Spain  6.9E-6**  1.6E-5** 6.6E-6**
[1.0E-6] [2.4E-6] [2.9E-6]
Income*Canada  -0.001*  -0.039* 0.036**
[0.0007] [0.022] [0.017]
High school+  -0.094** -0,034  -0.165**
[0.034] [0.043] [0.055]
High school+ *Spain -0,033 -0,117 0,092
[0.082] [0.079] [0.144]
High school+*Canada 0.104** -0,042 0.196**
[0.049] [0.079] [0.074]
_Constant 1.072** 1.264** 0.935**
[0.100] [0.125] [0.220]
Robust standard errors are reported in parentheses
Age corresponds to 4 age categories.
Sum ADL=preparing meals+shopping for groceries+doing light housework
+showering+walkingTable 9. US, Spain and UK
Dependent variable: SUM OF ADLs
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ALL POOR NON-POOR
Heart/Circulatory 0.080** 0.091** 0.033**
[0.013] [0.015] [0.014]
Heart/Circ*UK 0.092** 0.200* 0.056**
[0.032] [0.109] [0.024]
Heart/Circ*Spain 0.104** 0.343** 0.126**
[0.023] [0.057] [0.039]
Asthma/ Bronchitis 0.094** 0.090** 0.102**
[0.015] [0.017] [0.033]
Asthma/Bronch*UK 0,035 0,023 0,022
[0.074] [0.119] [0.096]
Asthma/Bronch*Spain 0,035 -0,005 -0,013
[0.043] [0.052] [0.076]
Skin/Allergy -0,112 -0,105 -0,133
[0.290] [0.341] [0.147]
Skin/Allergy*UK 0.213** 0.313** 0.256*
[0.106] [0.151] [0.151]
Skin/Allergy*Spain 0.087* 0.103** 0,073
[0.041] [0.051] [0.063]
Diabetes 0.383** 0.188** 0.335**
[0.017] [0.019] [0.038]
Diabetes*UK  -0.158*  -0.143**  -0.142**
[0.080] [0.065] [0.069]
Diabetes*Spain  -0.262**  -0.179**  -0.142**
[0.035] [0.043] [0.061]
Arthritis 0.149** 0.163** 0.107**
[0.013] [0.015] [0.027]
Arthritis*UK 0,128 0.235** 0,007
[0.101] [0.141] [0.143]
Arthritis*Spain 0,013 0,039 -0,013
[0.037] [0.045] [0.062]
Stomach 0.204** 0,067 0,336
[0.082] [0.124] [0.257]
Stomach*UK -0,108 -0,022 -0,159
[0.120] [0.174] [0.244]
Stomach*Spain -0,025 -0,028 -0,018
[0.091] [0.102] [0.065]
Sight 0.217** 0.210** 0.243**
[0.015] [0.017] [0.034]
Sight*UK  -0.158*  -0.124*  -0.250**
[0.094] [0.035] [0.120]
Sight*Spain  -0.192**  -0.169**  -0.257**
[0.036] [0.043] [0.071]
CONTINUED….Table 9 (continued)
Acute Versus Chronic Disease
A third explanation is suggested by our findings: the US does relatively better at
conditions where acute treatment is needed and relatively worse at chronic conditions.  The
comparison of heart disease and diabetes is particularly revealing.  Heart disease is frequently
treated in an acute setting, while diabetes is generally managed as a chronic disease.  This
could substantially influence the impact of medical care on health.  
Heart Disease.  Many individuals who report having had ischemic heart disease will
have suffered from an acute event – a heart attack, angina, or other related condition.  In such
cases, there are many acute therapies that can be performed, along with ongoing chronic care.
For a person who has a heart attack, for example, diagnostic surgical interventions such as
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ALL POOR NON-POOR
Hearing 0.032** 0.031** 0,039
[0.013] [0.015] [0.028]
Hearing*UK 0,048 -0,158 0,114
[0.080] [0.128] [0.101]
Hearing*Spain -0,009 -0,032 0,016
[0.033] [0.037] [0.071]
UK 0.405** 0,108 0.520**
[0.117] [0.254] [0.183]
Spain  -0.286**  -0.333**  -0.289**
[0.025] [0.052] [0.082]
Age  -0.250** -0,040  -0.325**
[0.043] [0.085] [0.050]
Age Square 0.059** 0.029* 0.070**
[0.008] [0.016] [0.009]
Male 0,120 0,186 0,128
[0.088] [0.149] [0.110]
Age* Male -0,086 -0,111 -0,095
[0.071] [0.125] [0.088]
Age Square*Male 0,014 0,003 0,020
[0.013] [0.024] [0.016]
Income  -2.4E-6**  -6.6E-6**  -2.9E-6**
[4.6E-7] [1.1E-6] [1.4E-6]
Income*UK -1,20E-05 3,10E-05 -1,20E-05
[8.7E-6] [5.9E-5] [1.1E-5]
Income*Spain 2.4E-6** 6.6E-6** 2.9E-6**
[4.6E-7] [1.1E-6] [1.4E-6]
High school+  -0.046** -0,019  -0.075**
[0.015] [0.019] [0.026]
High school+ *UK 0,005 0,318 -0,106
[0.104] [0.197] [0.113]
High school+*Spain 0,024 0,034 0,050
[0.024] [0.030] [0.040]
_constant 0.261** 0.648** 0.261**
[0.122] [0.068] [0.122]
Robust standard errors are reported in parentheses
* Significant at 10 percent
**Significant at 5 percent
Sum ADL=dressing+walkingcardiac catheterization may be used, and treatment may consist of intensive surgical
procedures such as open heart surgery or angioplasty.16 The medical literature shows that
these therapies can affect quality of life, in addition to length of life (Brorsson et al., 2002;
Sedrakyan at al., 2003; Hlatky et al., 1997).
Medical systems that spend a lot can afford much more of this high-tech care than
systems that spend less. The US spends the most on medical care and uses these intensive
procedures the most. This is shown empirically in Figures 2, 3, and 4, which present the
utilization rate for cardiac catheterization, bypass surgery, and angioplasty.  In each case, the
figures are scaled to the population as a whole.17 The US uses these procedures far more than
do other countries; use is three to five times greater in the US. The other three countries use
them much less, and do so at relatively similar rates.18
Figure 2. Utilization Rates for Cardiac Catheterization
(number per 100,000 people 20 or older)














16 Cardiac catheterization is a diagnostic test that involves passing a fine tube (catheter) through a blood vessel
to the heart and into a coronary artery.  Bypass surgery involves opening the chest wall and creating a new
blood path around the occluded artery.  Angioplasty is a technique for treating narrowing or occlusion of a
blood vessel or heart valve by introducing a balloon into the constricted area to widen it. 
17 Ideally, utilization would be scaled by the share of people with an acute heart disease incident, but such data
are not available.  
18 In the terminology of the TECH group, the US is an “early start/fast growth” country, Canada belonged to
the “late start/fast growth” group, and the UK to the “late start /slow growth” class. A similar conclusion
was reached by the OECD Study of Cross National Differences in the Treatment, Cost and Outcomes of
Ischaemic Heart Disease (2003), which concluded that a lot of the differences observed across countries are
due to the different health care systems. They found that Canada and the UK provide very limited
incentives to adopt cost-increasing new technologies due to their global budgets and strong programs to
regulate technology adoption. Figure 3. Utilization Rates for Coronary Angioplasty
(number per 100,000 people aged 20 and older)
Source: OECD Health Data, 2002.
Figure 4. Utilization Rates for Coronary Bypass
(number per 100,000 people aged 20 and older)




























USThis matches up with self-reported health of people with heart disease.  People with
heart disease in the US report themselves to be in substantially better health than people in
other countries, and the average in each of these other countries is roughly similar.19 Of
course, this does not prove that increased use of these procedures is the cause of improved
health.  To be more definitive about this, we would need to link data on self-reported health
with the particular diagnosis and treatment that an individual received; neither of these are
available in any of the data sets we examine. But the evidence is certainly consistent with the
theory.  Additional work using other data sets could usefully test these other predictions.
Diabetes. Diabetes mellitus is a chronic condition that impairs the body’s ability to
produce or store glucose. Type 1 diabetes is usually diagnosed in children and is a situation
where the pancreas produces little or no insulin. Type 2 diabetes is far more common
(accounting for 90 percent of diabetes cases) and occurs when the body does not effectively
use the insulin it produces.  Untreated, or poorly treated, diabetes can cause severe problems,
including vascular diseases (heart disease or stroke can result), small blood vessel disease (it
can lead to blindness or kidney disease) and nerve damage or neuropathy (it can lead to
amputation). Some of these complications are controlled for in our analysis (heart disease,
stroke, and visual problems), and thus complications along these lines would not be
associated with diabetes by itself. But not all complications would be picked up
independently (kidney disease and nerve damage, for example).  Better treatment of diabetes
could well improve health through these pathways.
Diabetes requires continuous monitoring and therapeutic intervention. Type 1
diabetes requires the intake of insulin regularly. Type 2 diabetes is controlled through
exercise and meal planning and possibly medications and/or insulin. This monitoring requires
a lot of self-commitment, including self-testing of blood (about four times a day) and
continuous diet and exercise control. This ongoing monitoring and treatment is provided in a
chronic care setting, in contrast to the acute care treatments that are a larger factor for people
with heart disease.
The success of the UK, Canada and, even more, Spain in the treatment of diabetes may
come from differences in how they organize chronic care for diabetes. In particular, these
countries stress a team-based approach that allows for an early detection of possible diabetes
complications; they also emphasize training patients in methods of self-care. For instance, in
Catalonia and in most of the other Spanish Autonomous Communities, the Diabetes Association
organizes education seminars for diabetics and their families in coordination with the regional
government. Also, in Catalonia some of the largest public hospitals have nurses exclusively
dedicated to the provision of education on diabetes for the patients and their families, and most
of the largest hospitals have nurses dedicated to educating on diabetes (but not full-time). Both
Canada and the UK have recently established different platforms for the integrated treatment and
monitoring of diabetes: in 1999 Canada started implementing the Canadian Diabetes Strategy, a
five year program that has the goal of improving the prevention and control of diabetes. The UK
has established the National Service Framework- Diabetes to determine the country’s standards
for the treatment, monitoring and prevention of diabetes.
The US, in contrast, has no such integrated approach. Patients are managed
individually by their primary care physician, with most of the onus for successful treatment on
the patient; most primary care physicians are ill-equipped to help people manage their disease.
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19 Related evidence suggesting that greater use of intensive care improves the health of Americans relative to
Canadians is in Pilote at al. (1994).  That study made direct comparisons of functional status but did not
normalize for the non-impaired group.   The failures of individuals in self-management of chronic disease are clear,
particularly in the case of diabetes.  Common measures of diabetes control suggest that no
more than 35 percent of diabetics in the US have their blood sugar below recommended
levels (American Diabetes Association) and a recent study from the US Center for Disease
Control and Prevention found that 71 percent of diabetics also had high blood pressure.
These numbers are much lower for Spain and Canada, where the percentage of diabetics with
high blood pressure are 45 (EPICARDIAN, 2003) and 47 (Health Canada, Diabetes in
Canada, 2002) respectively. Rates of medical examination for vision problems, problems
with blood flow to extremities, and other complications are also low.  As a result, diabetes
complications are frequent in the US.
Further, substantial evidence shows that outcomes can be improved with appropriate
chronic care interventions, of the type that occur elsewhere. Introducing systems that stress
physician monitoring, outreach, and appropriate interventions has been shown to result in
large improvements in diabetes outcomes (Beaulieu, Cutler, and Ho, 2002).
Thus, it is plausible that the poor organization of chronic disease care in the United
States relative to other countries explains the difference in health outcomes for people with
diabetes.  Again, this is not proof of this proposition.  But it suggests a type of data analysis
that can shed more light on this hypothesis.  Unfortunately, the data we examine do not have
information on the nature of diabetes care provided. Thus, this test will have to await the
analysis of other data.
V. Conclusions
The US spends much more on health care than Canada, Spain or the UK. The natural
question is whether that increased spending buys improved outcomes.  It has long been clear
that mortality as a whole is no better in the US than in other countries.  What was less clear is
whether there are differences in non-fatal health outcomes. Our results provide among the
first comparative looks at this question. 
We  present a mixed message: the US does much better for people with some
conditions (most particularly heart disease), but does worse on others (especially diabetes).
The discrepancy between high quality of life for some conditions and low quality of
life for others is not attributable to differing performance by income: the poor and non-poor
fare similarly in the US. Nor does it appear to be attributable to measurement issues in
determining a person’s quality of life. We suggest that the difference may have to do with the
nature of acute versus chronic disease care. The US tends to do better for conditions where
there is an acute component to treatment: the availability and use of acute care is significantly
greater in the US. The US does poorly, in contrast, for conditions requiring substantial
chronic disease management.  Countries that focus on this type of treatment seem to do much
better. We suggest this hypothesis, and provide guidance on tests that might confirm or
disprove it.
If this hypothesis is true, it raises the question about how medical systems are
organized to treat various types of conditions.  It may be that other countries focus on chronic
disease care because they are cognizant of the limits on acute care and this is a reasonable
substitute.  Alternatively, it may be easier to focus on non-high tech treatments outside of the
private market, where financial incentives are much less important.  The political economy of
medical system development, along with the exact nature for the results we observe, will
have to await further research.
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